HAEMATOLOGY
CBC -(COMPLETE BLOOD COUNT)
RBC PARAMETERS
HB -(Haemoglobin)
12.2
g/dL
13.0-18.0
Erythrocyte Count (RBC Count)
4.40
10^6/uL
4.0-5.2
Packed Cell Volume (PCV)-Hematocrit
37.3
%
34.0-40.0
Mean Corpuscular Volume (MCV)
84.77
fL
80 - 96
Mean Corpuscular Hemoglobin (MCH)
27.73
pg/cell
28 - 33
Mean Corpuscular Hb concentration (MCHC)
32.71
g/dL
31 - 36
RDW-CV
15.4
%
11.7 - 14.4
RDW-SD
48.1
fL
35.0- 46.0
WBC PARAMETERS
Total Leukocyte Count (TLC/WBC)
4700
/cumm
4000-11000
Differential Count of WBC
Polymorphs Neutrophil
46
%
30 - 70
Lymphocytes
45
%
30 - 50
Eosinophils
05
%
1 - 5
Monocytes
04
%
0 - 6
Basophil
00
%
0 - 1
ABSOLUTE LEUKOCYTE COUNTS
Absolute Neutrophil Count
2162.00
/cumm
1800-7800
Absolute Lymphocyte Count
2115.00
/cumm
1000-4800
Absolute Eosinophils Count
235.00
/cumm
0-450
Absolute Monocyte Count
188.00
/cumm
0-800
Absolute Basophil Count
0.00
/cumm
0-200
PLATELET PARAMETERS
Platelet Count
0.55
lakh/cumm
1.5-5.0
Mean Platelet Volume (MPV)
10.9
fL
7.10-12.50
PCT(Plateletcrit)
0.038
%
0.18 - 0.39
Platelet Distribution Width(PDW)
17.2
fL
8.30-18.0
BIOCHEMISTRY
Plasma Glucose (Fasting)
80.0
mg/dl
70 - 110
Glycosylated Haemoglobin
HbA1c
4.8
%
Normal: Below 6.0 %
Mean Blood Glucose (Calculated)
91.06
mg/dl
Comment

METHOD :- HPLC for HbA1C  by LD 500 (AspenA1c)

(NGSP Certified)


Glycosylated Haeamoglobin Blood :-

Current methods of assessing control in patient with diabtes mellitus include measurement of blood and plasma. These glucose measurements reflect acute changes and not the long term aspects of diabetic control. A more useful technique for assessing the control of diabetes is the measurement of glycosylated haemoglobins that is haemoglobin with glucose or glucose phosphate moieties bound to the amino terminal valine of one or both beta chaings.

The level of haemoglobin Alc, which comose 3% to 6% of the total haemoglobin in healthy individuals is proportional to both the average glucose concentration and the life span of the red blood cells in the circulation.The measurement or HbA1C has therefore been accepted for the clinical management of diabetes through routine monitoring.

Increased level of HbA1C correlate  with lack of glucose control. In diabetics with good glucose control the amount of HbA1C may return to the reference interval. specimens for patients with hemolytic anemia  will exhibit decrease glycosylated haemoglobin values due to shorted life span of the red cells.

specimens from patients with polycythemia or post-splenectomy may exhibit increase glycosylated haemoglobin values due to a somewhat longer life span of the red cells.

Blood Urea
26.0
mg/dl
05 - 43
Serum Creatinine
0.70
mg/dl
0.6 - 1.2
Comment

Decreased serum calcium values are found in hypoparathyroidism, rickets, osteiomalacia and steatorrhea. A fall in serum calcium can occun in acute pancreatitis and in those forms of renal disease in which excessive proteinuria is observed. Increased serum calcium values are observed in hyperparathyroidism, hypervitamonosis D and multiple myeloma.

LIPID PROFILE
Serum Total Cholesterol
145.0
mg/dl
Desirable: < 200
Serum Triglycerides
101.0
mg/dl
Desirable: < 160
Serum H.D.L. - Cholesterol
48.0
mg/dl
Desirable: > 60
Serum L.D.L. - Cholesterol
97.0
mg/dl
Desirable: < 130
Serum V.L.D.L Cholesterol
20.2
mg/dl
Desirable: < 23
Total Choles. / H.D.L Ratio
3.0
Ratio
Low Risk: 3.3 - 4.4
L.D.L. / H.D.L. Ratio
2.0
Ratio
Low Risk: 0.5 - 3.0
Comment

 

NOTE  :- Lipid profile range as per ncep – atp 111 are :

Serum cholestrol  (Total) :

Desirable: < 200 mg/dl, Borderline: 200-239 mg/dl, Elevated : >250 mg/dl.

Serum high – density lipoprotein cholterol (HDL):

Desirable: > 60 mg/dl,  Borderline: 40-60 mg/dl, Elevated : >70 mg/dl.

TOTAL cholestrol : HDL cholestrol:

Low risk :  3.3 - 4.4, Average risk : 4.4 – 7.1, Moderate risk : 7.1 – 11.0, High risk : >11.0

Serum low – density lipoprotein (LDL) cholesterol:

Desirable : < 100 mg/dl, Borderline: 100-159 mg/dl, Elevated : >160 mg/dl.

* It is ptreferable to measure lipid after 12 hrs fasting, as triglyceride levels rised and both HDL & LDL levels fall after fat containing meals.

* since serum lipid levels a vary widely from day to day( being largely dependaent on diet) , at least 2 - 3 measurments should be made days or weeks apart , before labelling a person as hyper lipidaemic/ normolipidaemic or before initiating therapy.
*Both LDL & HDL levels remains decreased for several weeks after acute inflammatory states, following myocardial infection, stress, trauma, surgery and recent illness.
* lipid profile values should always be corroborated in the light of clinical findings, dietary habits / axcess/ restrictions, effects of illness, exercise, inter & intra individual variations and drugs( Anabolic steroids, oral contraceptives) progestogens, antithypertensives, oestrogen, insulin & hydrochlorthiazide.

LFT (LIVER FUNCTION TEST)
Billirubin (Total & Direct & Indirect)
Total Billirubin
0.72
mg/dl
Adult: 0.1 - 1.2 mg/dl
Direct Billirubin
0.26
mg/dl
0 - 0.3 mg/dl
Indirect Billirubin
0.46
mg/dl
0.2 - 0.7 mg/dl
Serum SGOT(AST)
32.0
IU/L
10-40
Serum SGPT(ALT)
20.0
IU/L
5 - 40 IU/L
Alkaline Phosphatase
89.0
IU/L
Female : 64-306 IU/L
Total Protein (A:G)
Serum Protein
6.19
gm/dl
6.3 - 8.4 gm/dl
Albumin
3.93
gm/dl
3.5 - 5.0 gm/dl
Globulin
2.26
gm/dl
2.5 - 3.5 gm/dl
A:G Ratio
1.74
Ratio
1.5 - 3.1
Serum Uric Acid
5.89
mg/dl
2.5-6.8
Comment

Uric acid is the end product of nucleoprotein metabolism. It is a low threshold excretory product. the serum uric acid level is ofter raised in gout. the determination has diagnostic value differentiating gout from non gout arthritis. uric acid levels are also increased in renal failure, uremia and leukemia.

SEROLOGY
Australia Antigen (HbsAg)
NON-REACTIVE
Comment

NOTE : - TO BE CONFIRMED BY ELISA OR OTHER METHOD.

HBsAg is the surface antigen of the hepatitis B virus (HBV). It indicates current hepatitis B infection.

These antigen-proteins can be genetically manufactured (e.g. transgene E. coli) to produce material for a simple antigen test, which detects the presence of HBV. It is present in the sera of patients with viral hepatitis B (with or without clinical symptoms). Patients who developed antibodies against HBsAg (anti-HBsAg seroconversion) are usually considered non-infectious. HBsAg detection by immunoassay is used in blood screening, to establish a diagnosis of hepatitis B infection in the clinical setting (in combination with other disease markers) and to monitor antiviral treatment.
Positive HBsAg tests can be due to recent vaccination against Hepatitis B virus but this positivity is unlikely to persist beyond 14 days post-vaccination

ANTI HCV (Card Test)
NON REACTIVE
Comment

NOTE : - TO BE CONFIRMED BY ELISA OR OTHER METHOD.

Hepatitis C is an infectious disease affecting primarily the liver, caused by the hepatitis C virus (HCV).[1] The infection is often asymptomatic, but chronic infection can lead to scarring of the liver and ultimately to cirrhosis, which is generally apparent after many years. In some cases, those with cirrhosis will go on to develop liver failure, liver cancer, or life-threatening esophageal and gastric varices 

BIOCHEMISTRY
C-Reactive Protein(C R P)
2.45
mg/l
< 6 mg/l
Comment

METHOD: IMMUNOTURBIDIMETRIC


 The C -Reactive protein is normal alpha- globulin and it is elevated in patients who have an inflammatory conditions of infectious or noninfectious origin. The test is non specific and the resuts frequently overlap ESR values. The findings can be useful as a simple index of the disease ativity and treatment status.

CLINICAL PATHOLOGY
URINE ROUTINE EXAMINATION
Physical Examination
Volume
30 ML
ml
Colour
STROW
Appearance
CLEAR
Sediments
ABSENT
Specific Gravity
1.005
Chemical Examination
PH
ACIDIC
Sugar
NIL
Albumin
ABSENT
Bile Salt
ABSENT
Microscopic Examination
Erythrocytes
1-2/HPF
Pus cells
4-6/HPF
Epithelial Cells
2-3/HPF
/HPF